Pfizer and Sigma-Tau Announce an Agreement to Market a Potential New Treatment for Malaria

Pfizer IncPfizer Inc (Pfizer) and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A (Sigma-Tau), a privately owned Italian pharmaceutical company, have entered into a license and supply agreement under which, following applicable regulatory submissions and approvals, the companies will market Eurartesim®, a novel fixed dose artemisinin-based combination therapy (ACT), in Africa.

Eurartesim® (dihydroartemisinin + piperaquine), a Phase III product candidate, aims to treat uncomplicated Plasmodium falciparum malaria in adults and children, while reducing the potential for re-infection. The product candidate, developed jointly by Medicines for Malaria Venture (MMV) and Sigma-Tau, is expected to be filed for registration with the European Medicines Agency and the U.S. Food and Drug Administration in 2009. Eurartesim® has already been granted orphan drug status by both the European and U.S. regulatory authorities.

The World Health Organization (WHO) recommends that all uncomplicated malaria be treated with ACTs. This policy is designed to reduce drug resistance which has rendered the most widely used monotherapies, such as chloroquine, useless in many parts of the world.

Malaria continues to be an endemic disease in sub-Saharan Africa and is one of the leading causes of infant mortality. The WHO estimates 881,000 deaths worldwide due to malaria in 2006, of which more than 90 percent occurred in Africa.

"Pfizer is excited about our collaboration with Sigma-Tau," said Jean-Michel Halfon, president and general manager, Emerging Markets, Pfizer Inc. "The effective treatment of malaria, a preventable and treatable disease, is an essential need for patients in many countries in Africa and around the world. This agreement to make Eurartesim® available supports Pfizer's vision to serve the needs of patients in developing countries and to improve global access to essential medicines."

Under the agreement, Pfizer and Sigma-Tau will ensure access to this novel medicine in Africa in collaboration with the various local stakeholders. Following applicable regulatory submissions and approvals, Pfizer will market the drug in the public and private sectors locally in Africa, and Sigma-Tau will be responsible for the institutional sector. Further details of the financial terms were not disclosed.

"Sigma-Tau is delighted to announce this alliance with Pfizer. By combining our respective resources and expertise, we are confident we will powerfully tackle one of the greatest public health threats of all time," said Ugo Di Francesco, Vice President and Chief Executive Officer at Sigma-Tau. "Sigma-Tau is firmly committed to providing its contribution to the eradication of malaria. Throughout the past century and until 1964, when the last case of malaria was reported in Italy, our country fought, and finally won, the tough battle against malaria ("malaria" is, after all, an Italian word). Through the development of new, effective treatments such as Eurartesim®, we like to think that the same results can be achieved in countries, especially in Africa, where malaria continues to be an endemic disease."

"Currently, quality ACTs are practically non-existent in the private market in Africa, where many people get their anti-malarials" said Chris Hentschel, CEO and president of Medicines for Malaria Venture. "The Pfizer and Sigma-Tau alliance has the potential to make a huge impact in getting this life-saving medicine to those in need. As the co-developer of this medicine, we are delighted by this alliance because, ultimately, the measure of our success will be how many lives we can save."

About Pfizer
Pfizer discovers and develops innovative medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality healthcare and health system support.

About Pfizer's Philanthropic Programs in Malaria
Mobilize Against Malaria is Pfizer's latest initiative to help close critical gaps in malaria treatment and education in Senegal, Ghana and Kenya. At the 2006 Clinton Global Initiative, Pfizer announced a five-year (2007-2012) program to prevent infection and spread of malaria by improving malaria symptom recognition, treatment and referral through local grassroots training, education and awareness. Partners in this initiative include Family Health International and the Ghana Social Marketing Foundation in Ghana, Population Services International in Kenya and IntraHealth in Senegal. The London School of Hygiene and Tropical Medicine serves as the lead global evaluator, collaborating with local evaluation organizations on the ground.

To learn more about Pfizer's philanthropic programs, please visit http://www.pfizer.com/responsibility/.

About Sigma-Tau
Sigma-Tau is a leading, all Italian capital, international pharmaceutical group that invests in the research, development and marketing of innovative and effective treatments to improve patient well-being and quality of life. Sigma-Tau Group has headquarters in Pomezia (Rome, Italy), and subsidiaries in France, Switzerland, The Netherlands, Portugal, Germany, the UK and the USA, as well as in Spain and Sudan where the Group operates two production facilities. It has over 2500 employees and an extensive network of licensees worldwide.

Sigma-Tau was founded in Italy in 1957 and achieved a global turnover of € 665 million ($ 920 million) in 2007.

Sigma-Tau SpA consistently invests 16% of its annual turnover in R&D. Sigma-Tau's 400 R&D staff are currently running 43 R&D projects. A total of 14 NCEs and 12 known molecular entities in 30 different indications are at various stages of development.

Therapeutic areas in which the company's research and development are focused include metabolism, neurology, cardiovascular, oncology and immunology.

To learn more about Sigma-Tau, please visit: www.Sigma-Tau.it

Sigma-Tau's Malaria Programs
For several years now Sigma-Tau has focused in such area with a major social and health-care impact, namely the research and development of drugs for the treatment of rare diseases and malaria. In the case of malaria, the company's commitment has been made concrete by partnering with Medicines for Malaria Venture.

About Medicines for Malaria Venture (MMV)
Medicines for Malaria Venture (MMV) is a non-profit organization created to discover, develop and deliver effective and affordable anti-malarial drugs through public-private partnerships. Their vision is a world in which innovative medicines will cure and protect the millions at risk of malaria and help to ultimately eradicate this terrible disease.

MMV is currently managing the largest–ever portfolio of over 50 antimalarial projects in collaboration with over 100 pharmaceutical, academic, and endemic-country partners in 38 countries. The portfolio includes 19 completely new classes of compounds. New and improved treatment solutions are urgently needed for the 2.4 billion people at risk from malaria. MMV is working to ensure that its products will have the greatest possible public health impact and, most importantly, save lives.

For more information, please visit http://www.mmv.org.

Most Popular Now

How SARS-CoV-2 mutates to escape antibody binding

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the Uni...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Pfizer and BioNTech commence global clinical trial…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the saf...

Johnson & Johnson announces submission of appl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting E...

Could a nasal spray prevent coronavirus transmissi…

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the n...

European Commission purchases additional 150 milli…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an...

GSK and Vir Biotechnology expand coronavirus colla…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the resear...

Neandertal gene variants both increase and decreas…

Last year, researchers at Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany showed that a major genetic risk ...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...

Sinovac receives conditional marketing authorizati…

Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the China National Medical Produ...